Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.66 | N/A | +29.41% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.66 | N/A | +29.41% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of optimism about the company's direction. However, they did not offer specific guidance for the upcoming quarters.
Management highlighted the strong performance in their core business.
They expressed confidence in future growth despite not providing specific guidance.
Ligand Pharmaceuticals reported a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 1.47% on the day, likely due to the lack of revenue details and forward guidance. Investors may be cautious as they await more information on future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LOEWS CORP
Feb 8, 2016